Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-11-07
2006-11-07
Wax, Robert A. (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
07132398
ABSTRACT:
The present invention provides methods of treating hemorrhagic fevers where selective inhibitors of fVIIa/TF are used as a treatment for hemorrhagic fevers and have therapeutic effects which include ameliorating and/or preventing coagulopathy and inflammatory responses. These inhibitors include certain proteins which are part of a family termed Nematode-Extracted Anticoagulant Proteins (“NAPs”). Other inhibitors include Tissue Factor Pathway Inhibitor (“TFPI”) and TFPI analogs.
REFERENCES:
patent: 5650391 (1997-07-01), Schwartz et al.
patent: 5863894 (1999-01-01), Vlasuk et al.
patent: 5902582 (1999-05-01), Hung
patent: 6063764 (2000-05-01), Creasey et al.
patent: 6270764 (2001-08-01), Fisher et al.
patent: 6300100 (2001-10-01), Kamei et al.
patent: 6303295 (2001-10-01), Taylor et al.
patent: RE38008 (2003-02-01), Abrams et al.
patent: 6524567 (2003-02-01), Laub
patent: 6872808 (2005-03-01), Vlasuk et al.
patent: 2001/0018204 (2001-08-01), Papathanassiu et al.
patent: 2001/0028880 (2001-10-01), Fisher et al.
patent: 2001/0036932 (2001-11-01), Cardin et al.
patent: 2002/0077276 (2002-06-01), Fredeking et al.
patent: 2002/0164582 (2002-11-01), Hart et al.
patent: WO 00/30677 (2000-06-01), None
patent: WO 02/069960 (2002-09-01), None
patent: WO 02/069960 (2002-09-01), None
Moons et al., “Recombinant Nematode Anticoagulant Protein c2, a Novel Inhibitor of Tissue . . . ” Thromb. Haemost. 88:627-31, 2002.
Baize et al., “Inflammatory Responses in Ebola Virus-Infected Patients” Clin. Exp. Immunol. 128:163-168, 2002.
Bajaj et al., “Structure and Biology of Tissue Factor Pathway Inhibitor” Thromb. Haemost 86:959-72, 2001.
Bray et al., “Experimental Therapy of Filovirus Infections” Antiviral Res. 54:1-17, 2002.
Day, et al., “Recombinant Lipoprotein-Associated Coagulation Inhibitor Inhibits Tissue Thromboplastin-Induced . . . ” Blood 76(8):1538-1545, 1990.
Esmon et al., “Role of Coagulation Inhibitors in Inflammation” Thromb. Haemost 86:51-6, 2001.
Fisher-Hoch et al., “Pathophysiology of Shock and Hemorrhage in a Fulminating Viral Infection (Ebola)” J. of Infect. Dis. 152(5):887-894, 1985.
Kilgore et al., “Prospects for the Control of Bolivian Hemorrhagic Fever” Emerging Infect. Dis. 1(3):97-100, 1995.
Klenk et al., “Symposium on Marburg and Ebola Viruses”, Meeting Report, Virus Res. 80:117-123, 2001.
Mwanatambwe et al., “Ebola Hemorrhagic Fever (EHF): Mechanism of Transmission and Pathogenicity” J. Nippon Med. Sch. 68(5):370-375, 2001.
Okajima, K., “Regulation of Inflammatory Responses by Natural Anticoagulants” Immunol. Rev. 184:258-274, 2001.
Sanchez et al., “Reemergence of Ebola Virus in Africa” Emerging Infect. Dis. 1(3):96-97, 1995.
Takada et al., “The Pathogenesis of Ebola Hemorrhagic Fever” Trends in Microb. 9(10):506-511, 2001.
Wilson et al., “Ebola Virus: The Search for Vaccines and Treatments” Cell. and Mol. Life Sciences 58:1826-1841, 2001.
Weitz et al., New Anticoagulant Drugs Chest 119(1):95S-107S, 2001.
Abraham, et al., “Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: A multicenter, randomized, placebo-controlled, single-blind, dose escalation study”, Crit. Care Med. (2001) 29(11:2081-2089.
Baugh et al., “Regulation of extrinsic pathway factor Xa formation by tissue factor pathway inhibitor”, J. Biol. Chem. (1998) 273: 4378-4386.
Bernard et al., “Efficacy and safety of recombinant human activated Protein C for severe sepsis”, N. Engl. J. Med. (2001) 344:699-709.
Bock, P.E. et al., “Isolation of human blood coagulation α-Factor Xaby soybean trypsin inhibitor-sepharose chromatography and its active-site titration with fluorescein mono-p-guanidinobenzoate” Archives of Biocyhem, Biophys. 273: 375 (1989).
Borio, et al., “Hemorrhagic fever viruses as biological weapons”, JAMA (2002) 287(18):2391-2405.
Bouwman, et al., “Procoagulant and inflammatory response of virus-infected monocytes”, European J. Clin. Invest. (2002) 32:759-766.
Carson, “Computerized analysis of enzyme cascade reactions using continuous rate data obtained with an ELISA reader”, S.D. Comput. Prog. Biomed. 19: 151-157 (1985).
Creasey et al., “Tissue factor pathway inhibitor reduces mortality frommEscherichia coliseptic shock”, J. Clin. Invest. (1993) 91(6): 2850-2860.
deJonge et al., “Tissue factor pathway inhibitor does not influence inflammatory pathways during human endotoxemia”, J. Infect. Dis. (2001) 183(12): 1815-1818.
Despreaux CW, et al., “ThedacA gene ofBacillus stearothermophiluscoding for D-alanine carboxypeptidase: cloning, structure and expression inEscherichia coliandPichia pastoris”, Gene (1993) 131(1):35-41.
Doshi et al., “Evolving role of tissue factor and its pathway inhibitor”, Crit. Care. Med. (2002) 30(5 Suppl): 5241-5250.
Esmon C., “Protein C pathway in sepsis”, Annals of Medicine (2002) 34:598-605.
Geisbert et al., “Evaluation in nonhuman primates of vaccines against Ebola virus”. Emerging Infectious Diseases (2002) 8:503-507.
Hensley, et al., Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily, Immunology Letters (2002), 80:169-179.
Jespers et al., Surface expression and ligand-based selection of cDNAs fused to filamentous phage gene VI, Biotechnology (1995) 13, 378-382.
Laroche Y et al., “High-level secretion and very efficient isotopic labeling of tick anticoagulant peptide (TAP) expressed in the methyotrophic yeast,pichia pastoris”, Biotechnology (1994) 12, 1119-1124.
Leroy, et al., “Human asymphtomatic Ebola infection and stong inflammatory response”, The Lancet (2000), 355:2210-2215.
Morrison, J.F., and Walsh, C.T., “The behavior and significance of slowing-binding enzyme inhibitors”, Adv. Enzymol. 61:201-300 (1988).
Ruf, W., et al., Mutational analysis of receptor and cofactor function of tissue factor, Methods in Enzymology 222: 209-224 (1993).
Schou et al, “Marburg and Ebola virus infections in laboratory non-human primates: a literature review”, Comparative Medicine (2000) 50:108-123).
Ströher, et al., “Infection and activation of monocytes by Marburg and Ebola viruses”, Journal of Virology (2001), 75(22):11025-11033.
Taylor et al., “Active site inhibited factor VIIa (DEGR VIIa) attenuates the coagulant and interleukin-6 and -8, but not tumor necrosis factor, responses of the baboon to LD100Escherichra coli”, Blood (1998) 91:1609-1615.
Dendreon Corporation
Robins & Pasternak LLP
Wax Robert A.
LandOfFree
Method of treatment of hemorrhagic disease using a factor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treatment of hemorrhagic disease using a factor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treatment of hemorrhagic disease using a factor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3688855